Study of a new drug for advanced solid tumors
Part of Cancer clinical trials.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have an advanced solid tumor (cancer that has spread or can't be removed) that has gotten worse after standard treatment, or you can't take standard treatment.
- You must be able to walk and take care of yourself (ECOG score 0 or 1).
- You'll need to provide a recent sample of your tumor tissue for genetic testing or have results from an FGFR gene test.
- Your blood pressure must be well-controlled (systolic ≤150, diastolic ≤90).
- You cannot have taken certain medications or received certain cancer treatments within the past 4 weeks (or longer, depending on the drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new drug called CS231295 in people with advanced cancers (like lung, pancreatic, or brain tumors) that have stopped responding to standard treatments. The study aims to find the right dose and learn how well the drug works.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This trial tests a new drug (3HP-2827) for people with solid tumors that have spread or can't be removed surgically, and have changes in a gene called FGFR2. The goal is to see if the drug is safe and effective.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.